When to Escalate Hidradenitis Suppurativa Treatment Beyond Antibiotics
Understanding hidradenitis suppurativa (HS)
Hidradenitis suppurativa is a chronic, inflammatory skin disease that often surprises patients and clinicians with its unpredictability and severity.
People with HS typically experience painful nodules, recurrent abscesses, and sometimes long-lasting tunnels or sinus tracts under the skin, which can be physically disabling and emotionally draining.
The condition commonly affects areas with apocrine glands such as the underarms, groin, and under the breasts, and it can have a major impact on daily life and mental health (Source: American Academy of Dermatology Guidelines).
When to move beyond antibiotics
Many people with HS receive repeated courses of oral antibiotics, which can reduce inflammation in the short term but usually do not change the disease’s long-term course.
Clinicians typically consider stepping up treatment to biologic therapy when lesions keep returning despite adequate antibiotic trials, when sinus tracts or tunnels begin to form, when flares significantly interfere with daily activities, or when the patient’s disease advances by Hurley stage criteria (Source: American Academy of Dermatology Guidelines).
Delaying escalation risks cumulative scarring and the formation of chronic tunnels; by contrast, earlier use of targeted therapies can help prevent long-term tissue damage (Source: European S1 Guideline for Hidradenitis Suppurativa).
For patients who already have tunnels or multiple inflamed nodules, it is reasonable to use short-term antibiotics while initiating a biologic, but starting the biologic should not be postponed if it is clearly indicated (Source: American Academy of Dermatology Guidelines).
How aggressive should early treatment be?
HS does not follow neat, predictable response curves the way some conditions like psoriasis do, so treatment decisions need to be individualized.
Starting a biologic earlier in the disease course can meaningfully reduce inflammation, slow or prevent new tunnel formation, and improve pain and function for many patients (Source: PIONEER I and II phase 3 trials, AbbVie).
However, it’s important to set realistic expectations: complete, lasting remission can be difficult to achieve and frequently requires a combination of medical and surgical approaches rather than medication alone (Source: European S1 Guideline for Hidradenitis Suppurativa).
Clear, early conversations about goals — for example reducing flare frequency, cutting drainage, and improving mobility — help prevent frustration and “therapeutic fatigue” as care progresses.
What counts as treatment success?
Success in HS is rarely about perfectly clear skin; instead, meaningful improvement is measured by changes that affect daily life.
Key outcomes include fewer and shorter flares, prevention of new lesion formation, less redness and drainage, improved ability to move and exercise, and meaningful pain relief — all of which contribute to better quality of life (Source: American Academy of Dermatology Guidelines).
Once scarring and fibrosis have occurred, the skin may never return to a “normal” appearance even when inflammation is controlled, so objective lesion counts are less useful than patient-centered measures such as pain scores and quality-of-life instruments.
When to consider surgery
Surgery is not a last-resort option so much as a complementary tool that becomes necessary when certain problems persist.
Indications for surgical intervention include chronic, draining tunnels that do not respond to systemic therapy, extensive localized scarring that limits function, and recurrent abscesses in the same area despite medical management (Source: European S1 Guideline for Hidradenitis Suppurativa).
Medical treatments, including biologics, can reduce active inflammation but cannot reverse established fibrosis or scar tissue; delaying appropriate surgery can prolong pain and dysfunction and may limit eventual recovery.
What to do if a biologic stops working
It is common for response to a biologic to plateau over time in HS; this does not always mean the drug has failed altogether.
Strategies dermatologists use include adjusting dosing intervals where supported by evidence or the drug label, adding short-term adjunctive antibiotics to control flares, administering intralesional corticosteroid injections for isolated nodules, and re-checking adherence and modifiable triggers such as smoking or weight (Source: Humira (adalimumab) prescribing information; American Academy of Dermatology Guidelines).
If a patient’s underlying inflammation is controlled but persistent, localized lesions (such as fibrotic nodules or tunnels) remain, those lesions often need surgical removal or unroofing rather than more medical therapy.
In cases of true nonresponse to one biologic, switching to an alternative agent may help, but HS responses are variable and expectations should be realistic (Source: PIONEER I and II phase 3 trials, AbbVie).
Mental health and the psychosocial impact of HS
HS carries a heavy psychosocial burden: people with the condition commonly experience depression, anxiety, social withdrawal, workplace challenges, and sexual health concerns.
Treating HS effectively means addressing both the physical inflammation and the emotional fallout; routine screening for depression and other mental health conditions should be part of comprehensive HS care (Source: American Academy of Dermatology Guidelines).
Referrals to mental health professionals, support groups, or sexual health counselors can be an important part of restoring dignity, function, and quality of life.
The reality of long-term management
Managing HS requires patience and acceptance that progress is often incremental rather than instantaneous.
There isn’t a single, consistent “clear” endpoint that applies to every patient; many people achieve partial disease control and then work stepwise toward fewer flares and less tissue damage.
Experienced clinicians measure success by combining appropriate medical therapy, timely surgical intervention when needed, honest early conversations about expectations, and persistence despite setbacks (Source: European S1 Guideline for Hidradenitis Suppurativa; American Academy of Dermatology Guidelines).
With coordinated care, many patients can achieve meaningful improvement in pain, function, and quality of life — even if full clearance is not always possible.
Sources
- American Academy of Dermatology Association. Hidradenitis Suppurativa (HS) Clinical Guidelines and Management Recommendations (Source: American Academy of Dermatology Guidelines).
- European S1 Guideline for the treatment of hidradenitis suppurativa (acne inversa) — a consensus document on diagnosis and management (Source: European S1 Guideline for Hidradenitis Suppurativa).
- AbbVie. PIONEER I and PIONEER II phase 3 clinical trial data for adalimumab in hidradenitis suppurativa (Source: PIONEER I and II phase 3 trials, AbbVie).
- AbbVie. Humira (adalimumab) prescribing information and dosing guidance (Source: Humira (adalimumab) prescribing information, AbbVie).